Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

continuous cyclophosphamide and prednisolone followed by azathioprine and
prednisolone in lupus nephritis. Ann Rheum Dis 2003; 63: 525–529.
344 Fischer-Betz R, Chehab G, Sander O, Vordenbäumen S, Voiculescu A, Brinks R et al.
Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly
intravenous cyclophosphamide: a prospective observational study. J Rheumatol 2012; 39:
2111–7.
345 Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S et al. Prednisone in
lupus nephritis: how much is enough? Autoimmun Rev 2014; 13: 206–214.
346 Illei GG, Iii HAA, Crane M, Collins L, Gourley MF, Rn CHY. Combination therapy with
pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal
outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;
135: 248–257.
347 Mackworth-Young C, David J, Morgan S, Hughes G. A double blind, placebo controlled
trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis
1988; 47: 496–502.
348 Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus
erythematosus. Semin Arthritis Rheum 2003; 32: 370–377.
349 Zonana-nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus
erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801–
1808.
350 Thamer M, Hernán M, Zhang Y, Cotter D, Petri M. Relationship between prednisone,
lupus activity and permanet organ damage. J Rheumatol 2013; 36: 560–564.
351 Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina J-A, Moran M-A, Ruiz-Irastorza
G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.
Rheumatology 2014; 53: 1470–6.
352 Badsha H, Kong K, Lian T, Chan S, Edward C, Chng H. Low-dose pulse
methylprednisolone for systemic lupus erythematosus ares is ef cacious and has a
decreased risk of infectious complications. Lupus 2002; 11: 508–513.
353 Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra S V et al. Effects
of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across
multiple organ domains in patients with systemic lupus erythematosus: combined results
from two phase III trials. Ann Rheum Dis 2012; 71: 1833–1838.
354 Van Vollenhoven RF, Petri M a, Cervera R, Roth D a, Ji BN, Kleoudis CS et al.
Belimumab in the treatment of systemic lupus erythematosus: high disease activity
predictors of response. Ann Rheum Dis 2012; 71: 1343–1349.
355 Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R et al. Safety profile of
belimumab : pooled data from placebo-controlled phase 2 and 3 studies in patients with
systemic lupus erythematosus. Lupus 2013; 22: 144–154.
GUÍA DE PRÁCTICA CLÍNICA SOBRE LUPUS ERITEMATOSO SISTÉMICO 461